Handle With Care: Gilead Sciences, Inc. (NASDAQ: GILD)

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. The company’s stock has a 5-day price change of -0.93% and -8.05% over the past three months. GILD shares are trading -10.41% year to date (YTD), with the 12-month market performance down to -7.85% lower. […]

Value Hunters: Look To Gilead Sciences, Inc. (GILD)

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. The company’s stock has a 5-day price change of -2.73% and -10.42% over the past three months. GILD shares are trading -9.57% year to date (YTD), with the 12-month market performance down to -8.25% lower. […]

Gilead Sciences, Inc. (NASDAQ: GILD): The Best-Of-Breed For Investing?

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. Insiders at the company have transacted a total of 60 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 33 of these insider trades were purchases, […]

Uncovering Institutional Buying In Gilead Sciences, Inc. (NASDAQ: GILD)

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. Insiders at the company have transacted a total of 63 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 34 of these insider trades were purchases, […]

Gilead Sciences, Inc. (NASDAQ: GILD): Stock That Needs Special Handling

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. Insiders at the company have transacted a total of 63 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 34 of these insider trades were purchases, […]

Gilead Sciences, Inc. (GILD) Testing Investors’ Patience Right Now

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. Insiders at the company have transacted a total of 66 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 37 of these insider trades were purchases, […]

Gilead Sciences, Inc. (NASDAQ: GILD): Hunting Genuine Value In Market Debris

Currently, there are 1.25B common shares owned by the public and among those 1.24B shares have been available to trade. Insiders at the company have transacted a total of 70 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 39 of these insider trades were purchases, […]

Is Gilead Sciences, Inc. (NASDAQ: GILD) Back In The Buying Zone?

Capital Research & Management Co recently announced the acquisition of new stake in Gilead Sciences, Inc. (NASDAQ:GILD). The institutional investor has increased its shareholding in the Healthcare company by 0.98% to 81.72 million shares with purchase of 0.79 million shares. This fresh investment now brings its stake to 6.56% valued currently at $6.62 billion. In […]

Gilead Sciences, Inc. (NASDAQ: GILD) Hogging The Spotlight Today

Capital Research & Management Co recently announced the acquisition of new stake in Gilead Sciences, Inc. (NASDAQ:GILD). The institutional investor has increased its shareholding in the Healthcare company by 0.98% to 81.72 million shares with purchase of 0.79 million shares. This fresh investment now brings its stake to 6.56% valued currently at $6.62 billion. In […]